INVO Fertility, Inc.
IVFHealthcareNASDAQMedical Devices · Last scanned Oct 22, 2026
Scan Results
Daily timeframeINVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. At a $2.5M market cap, INVO Fertility, Inc. ranks as a micro-cap company within healthcare. It operates through Fertility Clinic Services and INVOcell Device segments.
Market Cap
$2.5M
Beta
1.44
P/E (TTM)
0.00
P/E (Fwd)
-0.07
EPS (TTM)
$128.17
EPS (Fwd)
$-8.00
ROE
-72.7%
ROA
-16.4%
Cash
$3.7M
Total Debt
$3.9M
Free CF
-$5.3M
52W Change
-97.9%
Annual Financials
Cash vs Debt
Where IVF stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IVF finished 59.73% below its 150-day moving average ($1.49) and 75.71% below its 200-day moving average ($2.47). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IVF overbought or oversold?
At the October 20, 2026 close, IVF's RSI(14) was 11.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
INVO Fertility, Inc. carries $3.9M in total debt against $3.7M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$5.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -72.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $822K (2022) to $6.8M (2025), reflecting a 732% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IVF.